We compiled evidence from a large national surgical database to identify the incidence, risk factors and postoperative impact of Clostridium difficile infection (CDI) in patients undergoing hip fracture repair.
Methods:
We identified 17,474 patients who underwent hip fracture repairs in 2015 using the ACS-NSQIP database. Interventions studied were open reduction/Internal fixation, total hip arthroplasty or hemiarthroplasty being performed for traumatic hip fractures. Outcomes studied were incidence, preoperative and postoperative risk factors for occurrence of CDI were studied using descriptive and statistical analysis.
Results:
A total of 92 patients (0.53%) developed CDI within 30 days of the operation. Following adjustment using multi-variate logistic regression, preoperative and hospital-associated factors associated with development of CDI were smoking (OR 1.75 [95% CI 1.03–2.99]), hypertension (OR 1.70 [95% CI 1.01–2.85]), hyponatraemia (OR 1.65 [95% CI 1.04–2.63]), prior systemic inflammatory response syndrome (SIRS) (OR 2.18 [95% CI 1.32-3.59]) and a length of stay >7 days (OR 1.98 [95% CI 1.11–3.53]. Postoperative factors associated with occurrence of CDI were occurrence of a deep surgical site infection (SSI) (OR 5.89 [95% CI 1.31–26.6]), a stay in the hospital >30 days (OR 6.56 [95% CI 2.56–16.9]) and unplanned reoperations (OR 2.78 [95% CI 1.29–5.99]).
Conclusion:
As we move toward an era of bundled-payment models, identification of risk factors associated with the occurrence of postoperative complications, such as CDI, will help curb excess healthcare utilisation and costs associated with the management of this complication.
ViscidiRWilleySBartlettJG.Isolation rates and toxigenic potential of Clostridium difficile isolates from various patient populations. Gastroenterology1981; 81: 5–9.
5.
CohenSHGerdingDNJohnsonS, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol2010; 31: 431–455.
6.
PeeryAFDellonESLundJ, et al. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology2012; 143: 1179–1187 e1–3.
7.
WiegandPNNathwaniDWilcoxMH, et al. Clinical and economic burden of Clostridium difficile infection in Europe: a systematic review of healthcare-facility-acquired infection. J Hosp Infect2012; 81: 1–14.
8.
Centers for Disease Control and Prevention (CDC). Vital signs: preventing Clostridium difficile infections. MMWR Morb Mortal Wkly Rep2012; 61: 157–162.
9.
ZhangSPalazuelos-MunozSBalsellsEM, et al. Cost of hospital management of Clostridium difficile infection in United States-a meta-analysis and modelling study. BMC Infect Dis2016; 16: 447.
ChalmersJDAkramARSinganayagamA, et al. Risk factors for Clostridium difficile infection in hospitalized patients with community-acquired pneumonia. J Infect2016; 73: 45–53.
12.
CampbellKAPhillipsMSStachelA, et al. Incidence and risk factors for hospital-acquired Clostridium difficile infection among inpatients in an orthopaedic tertiary care hospital. J Hosp Infect2013; 83: 146–149.
13.
Na’amnihWAdlerAMiller-RollT, et al. Incidence and risk factors for community and hospital acquisition of Clostridium difficile infection in the Tel Aviv Sourasky Medical Center. Infect Control Hosp Epidemiol2017; 38: 912–920.
14.
KumarappaVSPatelHShahA, et al. Temporal changes in serum albumin and total protein in patients with hospital-acquired Clostridium difficile infection. Ann Clin Lab Sci2014; 44: 32–37.
15.
SkovrljBGuzmanJZSilvestreJ, et al. Clostridium difficile colitis in patients undergoing lumbar spine surgery. Spine (Phila Pa 1976)2014; 39: E1167–1173.
16.
BovonratwetPBohlDDRussoGS, et al. Incidence, risk factors, and impact of Clostridium difficile colitis after spine surgery: an analysis of a national database. Spine (Phila Pa 1976)2018; 43: 861–868.
17.
GuzmanJZSkovrljBRothenbergES, et al. The burden of Clostridium difficile after cervical spine surgery. Global Spine J2016; 6: 314–321.
18.
BovonratwetPBohlDDMalpaniR, et al. Incidence, risk factors, and impact of Clostridium difficile colitis following primary total hip and knee arthroplasty. J Arthroplasty2018; 33: 205–210 e1.
19.
JenkinsPJTeohKSimpsonPM, et al. Clostridium difficile in patients undergoing primary hip and knee replacement. J Bone Joint Surg Br2010; 92: 994–998.
20.
GuliharANixonMJenkinsD, et al. Clostridium difficile in hip fracture patients: prevention, treatment and associated mortality. Injury2009; 40: 746–751.
21.
KakwaniRChakrabartiDKhanR, et al. Morbidity and mortality due to C. difficile infection in fracture neck of femur patients. J Bone Joint Surg Br2010; 92: 273–276.
22.
StarksIAyubGWalleyG, et al. Single-dose cefuroxime with gentamicin reduces Clostridium difficile-associated disease in hip-fracture patients. J Hosp Infect2008; 70: 21–26.
HamiltonBHKoCYRichardsK, et al. Missing data in the American College of Surgeons National Surgical Quality Improvement Program are not missing at random: implications and potential impact on quality assessments. J Am Coll Surg2010; 210: 125–139 e2.
26.
BouzaE.Consequences of Clostridium difficile infection: understanding the healthcare burden. Clin Microbiol Infect2012; 18(Suppl. 6): 5–12.
LealJGrayAMPrieto-AlhambraD, et al. Impact of hip fracture on hospital care costs: a population-based study. Osteoporos Int2016; 27: 549–558.
29.
BurgeRDawson-HughesBSolomonDH, et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res2007; 22: 465–475.
30.
AndersonPABernatzJSafdarN.Clostridium difficile Infection: an orthopaedic surgeon’s guide to epidemiology, management, and prevention. J Am Acad Orthop Surg2017; 25: 214–223.
31.
VanzantELOzrazgat-BaslantiTLiuH, et al. Clostridium difficile Infections after blunt trauma: a different patient population?Surg Infect (Larchmt)2015; 16: 421–427.
32.
EfronPALiuHLottenbergL, et al. A genomic analysis of Clostridium difficile infections in blunt trauma patients. J Trauma Acute Care Surg2013; 74: 334–338.
33.
LessaFCWinstonLGMcDonaldLC, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med2015; 372: 2369–2370.
34.
RogersMAGreeneMTSaintS, et al. Higher rates of Clostridium difficile infection among smokers. PLoS One2012; 7: e42091.
35.
BlixHSHjellvikVLitleskareI, et al. Cigarette smoking and risk of subsequent use of antibacterials: a follow-up of 365,117 men and women. J Antimicrob Chemother2011; 66: 2159–2167.
36.
PepinJSahebNCoulombeMA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis2005; 41: 1254–1260.
37.
SlimingsCRileyTV.Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. J Antimicrob Chemother2014; 69: 881–891.
38.
PearSMWilliamsonTHBettinKM, et al. Decrease in nosocomial Clostridium difficile-associated diarrhea by restricting clindamycin use. Ann Intern Med1994; 120: 272–277.
39.
WilcoxMHChalmersJDNordCE, et al. Role of cephalosporins in the era of Clostridium difficile infection. J Antimicrob Chemother2017; 72: 1–18.
40.
BohlDDBasquesBAGolinvauxNS, et al. Nationwide inpatient sample and national surgical quality improvement program give different results in hip fracture studies. Clin Orthop Relat Res2014; 472: 1672–1680.
